A comprehensive pipeline analysis reveals over 18 companies developing 20+ drug candidates for hypertriglyceridemia treatment, indicating significant industry investment in addressing this metabolic condition.
NorthSea Therapeutics appoints Melissa Bradford-Klug as CFO/CBO, bringing over 20 years of experience and $6 billion in financing track record to advance metabolic disease therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.